Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s)  by Drüeke, Tilman B. & Parfrey, Patrick S.
Summary of the KDIGO guideline on anemia and
comment: reading between the (guide)line(s)
Tilman B. Dru¨eke1 and Patrick S. Parfrey2
1Inserm Unit 1088, UFR de Me´decine et de Pharmacie, Universite´ de Picardie Jules Verne, Amiens, France; 2Health Sciences Center
St Johns, Newfoundland, Canada
The Kidney Disease Improving Global Outcomes (KDIGO)
clinical practice guideline for anemia in chronic kidney
disease (CKD) is designed to assist health-care providers in
treating CKD patients with anemia. A guideline is not
intended to define a standard of care, and should not be
construed as one, nor should it be interpreted as prescribing
an exclusive course of management. It is intended to provide
information and to allow the practitioner to make an
informed decision, based on evidence and expert judgment.
Every health-care professional making use of these
recommendations is responsible for evaluating the
appropriateness of applying them in any particular clinical
situation. Owing to the general nature of a guideline, it is
sometimes difficult to translate it to an individual patient’s
condition. As the primary goal is to improve patient care,
we have decided to focus on practical clinical aspects of
the KDIGO anemia guideline.
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The Kidney Disease Improving Global Outcomes (KDIGO)
Clinical practice guideline (CPG) for anemia in chronic
kidney disease (CKD) is based upon systematic literature
searches last conducted in October 2010, supplemented with
additional evidence through March 2012. It is designed to
provide information and assist decision making. The
potential benefits of CPGs are many. By providing clear
recommendation based on current evidence, CPGs can
improve the quality of clinical decisions. Evidence-based
guidelines support interventions that are of proven benefit
while documenting the quality of the supporting data.
Further, interventions unsupported by good science have
also been reviewed, and call attention to ineffective or even
harmful practices. On the flip side, there is also the possibility
that CPGs could have negative consequences. In the situation
in which only a few studies are of high enough quality, many
recommendations made by guideline committees are sub-
jective and ‘opinion based’. Importantly, despite good-quality
data, a recommendation may not be suitable for a particular
patient.1 Finally, applications of nonmedical values combined
with intense pressures on health-care provision can create an
environment for guideline misuse.2
Although CPGs have been shown to improve the quality
of care,3 whether they achieve this in daily practice is less
clear.1 In an analysis of 59 CPG evaluations covering a wide
range of clinical activities, all but four detected statistically
significant improvements in the process of medical care.
Moreover, all except 2 of the 11 that also measured the
outcome of care reported significant improvements in
outcome.3 Guidelines that are likely to change medical
practice have a few characteristics in common. First, they are
likely to be developed internally by the very physicians who
are going to use them. Second, appropriate development,
dissemination, and implementation strategies are adopted
during their introduction. Last, implementation strategies
that are operative within the doctor–patient consultation are
more likely to be effective.4
DEVELOPMENT OF THE KDIGO GUIDELINE FOR ANEMIA
Guideline development takes time, in general at least 2–3
years. For the KDIGO Anemia Guideline, an international
work group was created consisting of clinical experts in the
field of interest and an ‘evidence review team’ who are experts
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in the field of guideline development (using techniques
including systematic reviews and meta-analyses). The work
group formulated recommendations related to a specific
question or topic. Each set of recommendations was followed
by a ‘rationale’ section, which summarizes the evidence and
the reasoning for each recommendation and explains why
specific wording was chosen.
DO WE NEED A NEW ANEMIA GUIDELINE?
The optimal management of CKD-related anemia has been a
rapidly moving field in the past decade, with results being
published of an increasing number of large randomized
controlled trials of anemia correction using erythropoiesis-
stimulating agents (ESAs). These reports progressively
convinced the nephrology community that complete anemia
correction in patients with CKD and diabetes might be more
harmful than beneficial. ‘TREAT’, by far the largest, placebo-
controlled anemia correction trial in CKD, was published in
2009.5 It examined the effect of increasing hemoglobin (Hb)
levels with an ESA (darbepoetin) to a target of 13 g/dl, on
cardiovascular and kidney outcomes in over 4000 CKD stage
3–4 patients with diabetes. It failed to demonstrate a benefit
of full anemia correction, as compared with placebo with
no ESA use unless Hb decreased to a level below 9 g/dl.
Moreover, it showed a substantial increase in risk of stroke,
an increase in venous thromboembolic events, and a signal
that normalization of Hb with darbepoetin may be harmful
in patients with a history of malignancy.
Therapeutic decisions of the physician are based on the
continuous integration of new observations and the con-
tinuing need to balance the risks and benefits of treatment.
Because of the outcomes of recent studies of anemia
correction with ESAs or intravenous (i.v.) iron use, a new
assessment of the state of the art of anemia correction in
CKD and an update of recommendations for clinical practice
were deemed necessary.
Note that CPGs such as that of KDIGO are intended to
provide guidance, not a strict set of rules. The overarching
purpose of the recommendations is to assist in decision-
making, not provide a ‘cook book’ for clinical management.
This is because a guideline recommendation cannot account
for all possible variations of patient, provider, and system factors.
Thus, each health-care provider needs to assess the appro-
priateness of a particular recommendation or suggestion in a
specific context. Using examples of CKD-associated anemia,
we will attempt to show how the recommendations of the
guideline can be applied to the needs of individual patients.
CLINICAL EXAMPLES OF THE APPLICATION OF THE KDIGO
GUIDELINE FOR ANEMIA
Case 1
A 68-year-old male patient with CKD and insulin-treated
diabetes was referred in January 2012 for correction of severe
anemia and symptoms that were considered to be linked to it.
The patient had a history of ischemic heart disease, which
required the placement of two stents. He also had a history of
a transient cerebral ischemic attack and chronic obstructive
pulmonary disease, probably at least partially related to
long-standing smoking. Finally, the patient also had
immunoglobulin G lambda monoclonal gammopathy of
undetermined significance, diagnosed 3 years earlier. He was
receiving three antihypertensive agents, a statin, and low-dose
aspirin. His diabetes was well controlled.
On examination, his body weight was 95 kg, following
a loss of 10 kg during the preceding 6 months, body mass
index was 31 kg/m2, and BP was 135/88mmHg. Laboratory
examination revealed a serum creatinine level of 230 mmol/l
(2.6mg/dl) and an estimated glomerular filtration rate of
25ml/min per 1.73m2. His Hb was 9.2 g/dl, mean corpus-
cular volume 95 m3, reticulocyte count 30,000/mm3, white
blood cell count 8500/mm3, platelet count 350,000/mm3,
serum ferritin 110 ng/ml, and serum transferrin saturation
(TSAT) 21%.
First question: what is the cause of the anemia and what is
the best treatment? The nephrologist diagnosed possible folate
deficiency, based on a relatively high mean corpuscular
volume, in association with iron deficiency.
Here is the corresponding KDIGO recommendation:
Investigation of anemia. Guideline 1.3: In patients with
CKD and anemia (regardless of age and CKD stage), include
the following tests in initial evaluation of the anemia (not
graded):
K Complete blood count, which should include Hb
concentration, red cell indices, white blood cell count,
and differential and platelet count
K Absolute reticulocyte count
K Serum ferritin level
K TSAT
K Serum vitamin B12 and folate levels
It would have been preferable to measure the patient’s
serum folate level, but this recommendation is based on
opinion and therefore has not been graded. The nephrologist
opted for folate supplementation without measuring serum
folate: 5mg/day for 2 weeks, and subsequently 5mg/week for
another 6 weeks.
Second question: should the patient receive iron supplemen-
tation?
Here are the corresponding KDIGO recommendations.
Guideline 2.1.1: When prescribing iron therapy, balance the
potential benefits of avoiding or minimizing blood trans-
fusions, ESA therapy, and anemia-related symptoms against the
risks of harm in individual patients (e.g., anaphylactoid and
other acute reactions, unknown long-term risks) (not graded).
Guideline 2.1.2: For adult CKD patients with anemia not
on iron or ESA therapy, we suggest a trial of i.v. iron (or in
CKD non-dialysis (ND) patients alternatively a 1–3-month
trial of oral iron therapy) if (2C):
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K an increase in Hb concentration without starting ESA
treatment is desired and
K TSAT is p30% and ferritin is p500 ng/ml (p500mg/l).
The answer to the second question is yes. Serum ferritin
was below 500 ng/ml and TSAT below 30%. The patient had
no history of iron intolerance.
Third question: which is the optimal route of iron
administration?
Here is the corresponding KDIGO recommendation:
Guideline 2.1.4: For CKD ND patients who require iron
supplementation, select the route of iron administration on
the basis of the severity of iron deficiency, availability of
venous access, response to prior oral iron therapy, side effects
with prior oral or i.v. iron therapy, patient compliance, and
cost (not graded).
The nephrologist decided to supplement the patient with
both oral folate (see above) and i.v. iron. The iron was
administered in a 8-week course: one initial i.v. dose of
500mg and a second dose of 500mg 4 weeks later. Two weeks
after the second dose, Hb had increased from 9.2 to 9.6 g/dl,
serum ferritin to 350 ng/ml, and TSAT to 35%, whereas
mean corpuscular volume had decreased to 90 m3. The serum
folate level was then 20 ng/ml (normal, 3–16 ng/ml). Serum
C-reactive protein was 9mg/l, but there was no overt
inflammatory disease.
The degree of anemia correction was considered to be
insufficient. At this point, the options were (i) to proceed to a
second course of i.v. iron administration or (ii) to initiate
treatment with an ESA.
Here are the corresponding KDIGO recommendations:
Guideline 3.3: We recommend using ESA therapy with
great caution, if at all, in CKD patients with active
malignancy—in particular when cure is the anticipated
outcome—(1B), a history of stroke (1B), or a history of
malignancy (2C).
Guideline 3.4.2: For adult CKD ND patients with Hb
concentration o10.0 g/dl (o100 g/l), we suggest that the
decision to initiate ESA therapy be individualized based on
the rate of decrease of Hb concentration, prior response to
iron therapy, the risk of needing a transfusion, the risks
related to ESA therapy, and the presence of symptoms
attributable to anemia (2C).
The nephrologist opted for ESA therapy. This decision
was based on unsatisfactory response to i.v. iron despite a
TSAT increase over 30%. However, a second i.v. iron course
could have been administered, as serum ferritin was still
below 500 ng/ml and the patient had a history of transient
cerebral ischemia and therefore should be considered at
increased risk for stroke when receiving ESA therapy.
The problem also was that the patient’s veins were difficult
to puncture.
After 4 weeks of ESA therapy given subcutaneously, the
Hb increased only from 9.6 to 9.7 g/dl, with the serum
ferritin level falling from 350 to 300 ng/ml and the TSAT
from 35 to 31%. Therefore, the diagnosis of ESA hypo-
responsiveness was made and the ESA dose was not increased
because of the history of stroke and ischemic heart disease.
The possibility of adjuvant therapy was considered but
abandoned.
The corresponding KDIGO recommendation is the
following:
Adjuvant therapies. Guideline 3.16.2: We suggest not
using adjuvants to ESA treatment including vitamin C,
vitamin D, vitamin E, folic acid, L-carnitine, and pentoxifyl-
line (2D).
The nephrologist then decided not to escalate ESA dosing
but to explore various causes of ESA hyporesponsiveness.
The corresponding KDIGO recommendations are the
following:
Initial ESA hyporesponsiveness. Guideline 3.13.1: Classify
patients as having ESA hyporesponsiveness if they have no
increase in Hb concentration from baseline after the first
month of ESA treatment on appropriate weight-based dosing
(not graded).
Guideline 3.13.2: In patients with ESA hyporesponsive-
ness, we suggest avoiding repeated escalations in ESA dose
beyond double the initial weight-based dose (2D).
Management of poor ESA responsiveness. Guideline 3.15.1:
Evaluate patients with either initial or acquired ESA
hyporesponsiveness and treat for specific causes of poor
ESA response (not graded).
Many possible causes may lead to relative or absolute
resistance to ESA therapy, as shown in the Table 1.
The search for the underlying cause of ESA hyporespon-
siveness stimulated various examinations, including a bone
Table 1 | Potentially correctable versus non-correctable
factors involved in the anemia of CKD, in addition to
erythropoietin deficiency (reproduced from KDIGO Guideline





















Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; CKD, chronic kidney
disease; PRCA, pure red cell aplasia.
954 Kidney International (2012) 82, 952–960
rev iew TB Dru¨eke and PS Parfrey: KDIGO guideline on anemia—summary and comment
marrow biopsy. It led to the diagnosis of myelodysplastic
syndrome, subtype ‘refractory cytopenia with unilineage
dysplasia’. The myelodysplastic syndrome is a heterogeneous
group of closely related clonal hematopoietic disorders.
Patients with monoclonal gammopathy of undetermined
significance, as was the case here, have an eightfold higher
risk to develop acute myeloid leukemia or myelodysplastic
syndrome as compared with the general population.6
Because of the patient’s resistance to usually recom-
mended ESA dose, a treatment attempt with ‘hematologic’
ESA doses should be discussed. Indeed, studies in myelodys-
plastic syndrome have shown that ESA may decrease the
need for transfusion and increase survival. This treatment
involves the administration of 30,000–60,000 IU of epoetin-
alfa or epoetin-beta, or 150–300 mg of darbepoetin-alfa per
week (i.e., 3 to 6 times the weight-based dose for a 95-kg-
body-weight person). It requires weekly hematological testing
for 12 weeks and treatment reevaluation every 4 weeks.
Because of the high vascular risk profile of the patient, the
ESA dose was only cautiously increased to three times the
weight-based dose. The patient’s short-term response was an
increase in Hb to 10.2 g/dl.
This approach was not in contradiction to the following
KDIGO recommendation:
Guideline 3.15.2: For patients who remain hyporesponsive
despite correcting treatable causes, we suggest individuali-
zation of therapy, accounting for relative risks and benefits
of (2D):
K decline in Hb concentration
K continuing ESA, if needed to maintain Hb concentration,
with due consideration of the doses required, and
K blood transfusions
However, the very high ESA dose would go against the
spirit of the following KDIGO recommendation:
Guideline 3.13.2: In patients with ESA hyporesponsive-
ness, we suggest avoiding repeated escalations in ESA dose
beyond double the initial weight-based dose (2D).
The nephrologist chose to give a cautious trial of
hematologic ESA doses with modest effect on the Hb.
Subsequently, one should probably reduce the ESA dose to
about two times the weight-based dose in this high-risk
patient if one was to adhere to the opinion of the KDIGO
Work Group. Note, however, that in hyporesponsive patients
there is no randomized data on the optimal doses of ESA.
Case 2
A 50-year-old female patient with CKD due to reflux
nephropathy was referred in March 2009 because of
progressive worsening of anemia and asthenia. She was
clinically stable. She had no symptoms of urinary or other
infection. Her medical history was unremarkable.
On examination, her body weight was 65 kg, her body
mass index was 26 kg/m2, and her BP was 125/80mmHg.
Laboratory examination revealed a serum creatinine level of
210 mmol/l (2.4mg/dl) and an estimated glomerular filtration
rate of 25ml/min 1.73m2. Her Hb was 9.7 g/dl, mean
corpuscular volume 88 m3, reticulocyte count 45,000/mm3,
white blood cell count 7200/mm3, platelet count 240,000/
mm3, serum ferritin 41 ng/ml, and TSAT 20%. Serum folate
and vitamin B12 levels were normal.
The nephrologist concluded that iron deficiency was the
most probable diagnosis of the anemia in association with
CKD stage 4. Should any additional investigations be
undertaken?
Here is the corresponding KDIGO recommendation:
Investigation of anemia. Guideline 1.3: In patients with
CKD and anemia (regardless of age and CKD stage), include
the following tests in initial evaluation of the anemia (not
graded):
K Complete blood count, which should include Hb
concentration, red cell indices, white blood cell count,
and differential and platelet count
K Absolute reticulocyte count
K Serum ferritin level
K TSAT
K Serum vitamin B12 and folate levels
Although all the recommended investigations have been
carried out, consideration should be given to the investiga-
tion of gastrointestinal bleeding.
The patient was given a course of i.v. iron, 200mg per
week for 3 weeks. The treatment was well tolerated. The Hb
rose from 9.7 to 11.3 g/dl, the serum ferritin to 306 ng/ml,
and the TSAT to 32% 2 months later. However, after a further
2 months, the Hb was again down to 9.6 g/dl, the ferritin to
238 ng/ml, and the TSAT to 25%. Another course of i.v. iron
could be contemplated, but the nephrologist decided to
initiate ESA therapy. Would this fit the present KDIGO
guideline? As the i.v. iron was well tolerated and as there was
no particular venous access problem, additional courses of
i.v. iron would be the preferred treatment modality at present.
Here are again the corresponding KDIGO recommenda-
tions:
Guideline 2.1.1: When prescribing iron therapy, balance
the potential benefits of avoiding or minimizing blood
transfusions, ESA therapy, and anemia-related symptoms
against the risks of harm in individual patients (e.g.,
anaphylactoid and other acute reactions, unknown long-
term risks) (not graded).
Guideline 2.1.2: For adult CKD patients with anemia not
on iron or ESA therapy, we suggest a trial of i.v. iron (or in
CKD ND patients alternatively a 1–3-month trial of oral iron
therapy) if (2C):
K an increase in Hb concentration without starting ESA
treatment is desired and
K TSAT is p30% and ferritin is p500 ng/ml (p500mg/l).
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Would the decision to initiate ESA therapy be incompatible
with the present KDIGO recommendations? The answer is no.
The patient had no history of malignancy or ongoing, active
malignancy and no history of stroke. She suffered from fatigue.
She did not wish to have repeated courses of i.v. iron therapy.
Here are again the corresponding KDIGO recommen-
dations:
Guideline 3.3: We recommend using ESA therapy with great
caution, if at all, in CKD patients with active malignancy—
in particular when cure is the anticipated outcome—(1B),
a history of stroke (1B), or a history of malignancy (2C).
Guideline 3.4.2: For adult CKD ND patients with Hb
concentration o10.0 g/dl (o100 g/l), we suggest that the
decision to initiate ESA therapy be individualized based on
the rate of fall of Hb concentration, prior response to iron
therapy, the risk of needing a transfusion, the risks related to
ESA therapy, and the presence of symptoms attributable to
anemia (2C).
ESA treatment consisted of the administration of darbe-
poetin alfa, 60mgQ2W subcutaneously. Oral ferrous fumarate,
325mg once daily, was prescribed as well. Two months later,
the Hb rose to 12.4 g/dl, although the ferritin decreased to 169
and the TSAT to 22%. The patient confessed that she had
interrupted the oral iron treatment because of gastrointestinal
intolerance. She refused new courses of i.v. iron.
Three months later, she was admitted to the hospital
because of fever due to acute left-sided pyelonephritis. She
had cloudy urine, with urine culture growing Escherichia coli.
Antibiotic treatment with i.v. cephalosporin and gentamicin
was started.
Laboratory examination showed a white blood cell count
of 14,500/mm3 and a serum C-reactive protein of 146mg/l.
The Hb was 7.8 g/dl, serum ferritin was 530 ng/ml, and TSAT
was 18% despite ongoing ESA therapy. The patient was
transfused with 2 units of blood because she felt extremely
weak. Would the transfusion be indicated according to the
present recommendations?
Here are the corresponding KDIGO recommendations:
Use of red cell transfusion in chronic anemia. Guideline
4.1.1: When managing chronic anemia, we recommend
avoiding, when possible, red cell transfusions to minimize
the general risks related to their use (1B).
Guideline 4.1.2: In patients eligible for organ transplantation,
we specifically recommend avoiding, when possible, red cell
transfusions to minimize the risk of allosensitization (1C).
Guideline 4.2.1: When managing chronic anemia, we
suggest that the benefits of red cell transfusions may
outweigh the risks in patients in whom (2C):
K ESA therapy is ineffective (e.g., hemoglobinopathies,
bone marrow failure, ESA resistance)
K The risks of ESA therapy may outweigh its benefits (e.g.,
previous or current malignancy, previous stroke)
Guideline 4.2.2: We suggest that the decision to transfuse a
CKD patient with nonacute anemia should not be based on
any arbitrary Hb threshold, but should be determined by the
occurrence of symptoms caused by anemia (2C).
Thus, the answer to the question whether blood transfu-
sion would be indicated according to the present recom-
mendations is questionable. Under the condition of acute
infections, ESA responsiveness is decreased and may be even
entirely lost. In such cases, increasing ESA dose generally does
not improve the anemia, and blood transfusion may become
necessary. Consequently, one needs to balance the benefit of
transfusion in treating the weakness and the risks of
allosensitization, particularly as this young woman may need
a renal transplant in the future.
After recovery from acute pyelonephritis, the Hb stayed
stable between 11.3 and 12.1 g/dl with darbepoetin alfa,
60 mgQ2W. Eight months later, a Hb level of 13.7 g/dl was
reported by the laboratory. The question arose whether
the ESA dose should be reduced or even temporarily
interrupted. The nephrologist decided to check for this
unexpected Hb value first by recalling the patient and having
an immediate repeat determination. The Hb value that was
obtained the second time was 11.7 g/dl. Thus, the high level
of 13.7 g/dl turned out to be a laboratory error. The request
of a second Hb determination would be in line with present
recommendations, in particular to take into account clinical
circumstances, as there was no reasonable explanation for the
observed sudden increase in Hb concentration.
Here are the corresponding KDIGO recommendations:
ESA dosing. Guideline 3.8.2: We recommend that ESA
dose adjustments be made based on the patient’s Hb
concentration, rate of change in Hb concentration, current
ESA dose, and clinical circumstances (1B).
Guideline 3.8.3: We suggest decreasing the ESA dose in
preference to withholding ESA when a downward adjustment
of Hb concentration is needed (2C).
CONCLUSION
We hope that the presentation of these two cases shows the
usefulness of the KDIGO CPG for anemia in CKD, in
assisting practitioners to manage the anemia of their patients
in the most appropriate way. We would like to stress again
that KDIGO recommendations are meant to guide the
clinician, not to prescribe an exclusive treatment schedule.
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APPENDIX
Summary of Recommendation Statements
Chapter 1: Diagnosis and evaluation of anemia in CKD
TESTING FOR ANEMIA
Frequency of testing for anemia.
1.1.1: For CKD patients without anemia (as defined below in Recommendation 1.2.1 for adults and Recommendation 1.2.2
for children), measure Hb concentration when clinically indicated and (Not Graded):
K at least annually in patients with CKD 3
K at least twice per year in patients with CKD 4–5ND
K at least every 3 months in patients with CKD 5HD and CKD 5PD
1.1.2: For CKD patients with anemia not being treated with an ESA, measure Hb concentration when clinically indicated and
(Not Graded):
K at least every 3 months in patients with CKD 3–5ND and CKD 5PD
K at least monthly in patients with CKD 5HD
[See Recommendations 3.12.1–3.12.3 for measurement of Hb concentration in patients being treated with ESA.]
Diagnosis of anemia.
1.2.1: Diagnose anemia in adults and children415 years with CKD when the Hb concentration iso13.0 g/dl (o130 g/l) in
males and o12.0 g/dl (o120 g/l) in females. (Not Graded)
1.2.2: Diagnose anemia in children with CKD if Hb concentration is o11.0 g/dl (o110 g/l) in children 0.5–5 years,
o11.5 g/dl (115 g/l) in children 5–12 years, and o12.0 g/dl (120 g/l) in children 12–15 years. (Not Graded)
Investigation of anemia.
1.3: In patients with CKD and anemia (regardless of age and CKD stage), include the following tests in initial evaluation
of the anemia (Not Graded):
K Complete blood count (CBC), which should include Hb concentration, red cell indices, white blood cell count
and differential, and platelet count
K Absolute reticulocyte count
K Serum ferritin level
K Serum transferrin saturation (TSAT)
K Serum vitamin B12 and folate levels
Chapter 2: Use of iron to treat anemia in CKD
TREATMENT WITH IRON AGENTS.
2.1.1: When prescribing iron therapy, balance the potential benefits of avoiding or minimizing blood transfusions, ESA
therapy, and anemia-related symptoms against the risks of harm in individual patients (e.g., anaphylactoid and other
acute reactions, unknown long-term risks). (Not Graded)
2.1.2: For adult CKD patients with anemia not on iron or ESA therapy we suggest a trial of IV iron (or in CKD ND patients
alternatively a 1–3 month trial of oral iron therapy) if (2C):
K an increase in Hb concentration without starting ESA treatment is desired (Based on patient symptoms and overall
clinical goals, including avoidance of transfusion, improvement in anemia-related symptoms, and after exclusion of
active infection.) and
K TSAT is p30% and ferritin is p500 ng/ml (p500mg/l)
2.1.3: For adult CKD patients on ESA therapy who are not receiving iron supplementation, we suggest a trial of IV iron (or in
CKD ND patients alternatively a 1–3 month trial of oral iron therapy) if (2C):
K an increase in Hb concentration (Consistent with Recommendations #3.4.2 and 3.4.3.) or a decrease in ESA
dose is desired (Based on patient symptoms and overall clinical goals including avoidance of transfusion and
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improvement in anemia-related symptoms, and after exclusion of active infection and other causes of ESA
hyporesponsiveness.) and
K TSAT is p30% and ferritin is p500 ng/ml (p500mg/l)
2.1.4: For CKD ND patients who require iron supplementation, select the route of iron administration based on the severity
of iron deficiency, availability of venous access, response to prior oral iron therapy, side effects with prior oral or IV iron
therapy, patient compliance, and cost. (Not Graded)
2.1.5: Guide subsequent iron administration in CKD patients based on Hb responses to recent iron therapy, as well as ongoing
blood losses, iron status tests (TSAT and ferritin), Hb concentration, ESA responsiveness and ESA dose in ESA treated
patients, trends in each parameter, and the patient’s clinical status. (Not Graded)
2.1.6: For all pediatric CKD patients with anemia not on iron or ESA therapy, we recommend oral iron (or IV iron in CKD
HD patients) administration when TSAT is p20% and ferritin is p100 ng/ml (p100 mg/l). (1D)
2.1.7: For all pediatric CKD patients on ESA therapy who are not receiving iron supplementation, we recommend oral iron
(or IV iron in CKD HD patients) administration to maintain TSAT420% and ferritin4100 ng/ml (4100 mg/l). (1D)
IRON STATUS EVALUATION.
2.2.1: Evaluate iron status (TSAT and ferritin) at least every 3 months during ESA therapy, including the decision to start or
continue iron therapy. (Not Graded)
2.2.2: Test iron status (TSAT and ferritin) more frequently when initiating or increasing ESA dose, when there is blood loss,
when monitoring response after a course of IV iron, and in other circumstances where iron stores may become depleted.
(Not Graded)
CAUTIONS REGARDING IRON THERAPY.
2.3: When the initial dose of IV iron dextran is administered, we recommend (1B) and when the initial dose of IV
nondextran iron is administered, we suggest (2C) that patients be monitored for 60minutes after the infusion, and that
resuscitative facilities (including medications) and personnel trained to evaluate and treat serious adverse reactions be
available.
Iron during infection.
2.4: Avoid administering IV iron to patients with active systemic infections. (Not Graded)
Chapter 3: Use of ESAs and other agents to treat anemia in CKD
ESA INITIATION.
3.1: Address all correctable causes of anemia (including iron deficiency and inflammatory states) prior to initiation of ESA
therapy. (Not Graded)
3.2: In initiating and maintaining ESA therapy, we recommend balancing the potential benefits of reducing blood
transfusions and anemia-related symptoms against the risks of harm in individual patients (e.g., stroke, vascular access
loss, hypertension). (1B)
3.3: We recommend using ESA therapy with great caution, if at all, in CKD patients with active malignancy—in particular
when cure is the anticipated outcome—(1B), a history of stroke (1B), or a history of malignancy (2C).
3.4.1: For adult CKD ND patients with Hb concentration X10.0 g/dl (X100 g/l), we suggest that ESA therapy not be
initiated. (2D)
3.4.2: For adult CKD ND patients with Hb concentrationo10.0 g/dl (o100 g/l) we suggest that the decision whether to initiate
ESA therapy be individualized based on the rate of fall of Hb concentration, prior response to iron therapy, the risk of
needing a transfusion, the risks related to ESA therapy and the presence of symptoms attributable to anemia. (2C)
3.4.3: For adult CKD 5D patients, we suggest that ESA therapy be used to avoid having the Hb concentration fall below 9.0 g/dl
(90 g/l) by starting ESA therapy when the hemoglobin is between 9.0–10.0 g/dl (90–100 g/l). (2B)
3.4.4: Individualization of therapy is reasonable as some patients may have improvements in quality of life at higher Hb
concentration and ESA therapy may be started above 10.0 g/dl (100 g/l). (Not Graded)
3.4.5: For all pediatric CKD patients, we suggest that the selection of Hb concentration at which ESA therapy is initiated in the
individual patient includes consideration of potential benefits (e.g., improvement in quality of life, school attendance/
performance, and avoidance of transfusion) and potential harms. (2D)
ESA MAINTENANCE THERAPY.
3.5.1: In general, we suggest that ESAs not be used to maintain Hb concentration above 11.5 g/dl (115 g/l) in adult patients
with CKD. (2C)
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3.5.2: Individualization of therapy will be necessary as some patients may have improvements in quality of life at Hb
concentration above 11.5 g/dl (115 g/l) and will be prepared to accept the risks. (Not Graded)
3.6: In all adult patients, we recommend that ESAs not be used to intentionally increase the Hb concentration above 13 g/dl
(130 g/l). (1A)
3.7: In all pediatric CKD patients receiving ESA therapy, we suggest that the selected Hb concentration be in the range of
11.0 to 12.0 g/dl (110 to 120 g/l). (2D)
ESA DOSING.
3.8.1: We recommend determining the initial ESA dose using the patient’s Hb concentration, body weight, and clinical
circumstances. (1D)
3.8.2: We recommend that ESA dose adjustments be made based on the patient’s Hb concentration, rate of change in Hb
concentration, current ESA dose and clinical circumstances. (1B)
3.8.3: We suggest decreasing ESA dose in preference to withholding ESAwhen a downward adjustment of Hb concentration is
needed. (2C)
3.8.4: Re-evaluate ESA dose if (Not Graded):
K The patient suffers an ESA-related adverse event
K The patient has an acute or progressive illness that may cause ESA hyporesponsiveness (See Recommendations
3.13.1–3.13.2)
ESA ADMINISTRATION.
3.9.1: For CKD 5HD patients and those on hemofiltration or hemodiafiltration therapy, we suggest either intravenous or
subcutaneous administration of ESA. (2C)
3.9.2: For CKD ND and CKD 5PD patients, we suggest subcutaneous administration of ESA. (2C)
Frequency of administration.
3.10: We suggest determining the frequency of ESA administration based on CKD stage, treatment setting, efficacy
considerations, patient tolerance and preference, and type of ESA. (2C)
TYPE OF ESA.
3.11.1: We recommend choosing an ESA based on the balance of pharmacodynamics, safety information, clinical outcome
data, costs, and availability. (1D)
3.11.2: We suggest using only ESAs that have been approved by an independent regulatory agency. Specifically for ‘copy’
versions of ESAs, true biosimilar products should be used. (2D)
EVALUATING AND CORRECTING PERSISTENT FAILURE TO REACH OR MAINTAIN INTENDED HEMOGLOBIN CONCENTRATION
Frequency of monitoring.
3.12.1: During the initiation phase of ESA therapy, measure Hb concentration at least monthly. (Not Graded)
3.12.2: For CKD ND patients, during the maintenance phase of ESA therapy measure Hb concentration at least every
3 months. (Not Graded)
3.12.3: For CKD 5D patients, during the maintenance phase of ESA therapy measure Hb concentration at least monthly.
(Not Graded)
Initial ESA hyporesponsiveness.
3.13.1: Classify patients as having ESA hyporesponsiveness if they have no increase in Hb concentration from baseline after
the first month of ESA treatment on appropriate weight-based dosing. (Not Graded)
3.13.2: In patients with ESA hyporesponsiveness, we suggest avoiding repeated escalations in ESA dose beyond double the
initial weight-based dose. (2D)
Subsequent ESA hyporesponsiveness.
3.14.1: Classify patients as having acquired ESA hyporesponsiveness if after treatment with stable doses of ESA, they require 2
increases in ESA doses up to 50% beyond the dose at which they had been stable in an effort to maintain a stable Hb
concentration. (Not Graded)
3.14.2: In patients with acquired ESA hyporesponsiveness, we suggest avoiding repeated escalations in ESA dose beyond
double the dose at which they had been stable. (2D)
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Management of poor ESA responsiveness.
3.15.1: Evaluate patients with either initial or acquired ESA hyporesponsiveness and treat for specific causes of poor ESA
response. (Not Graded)
3.15.2: For patients who remain hyporesponsive despite correcting treatable causes, we suggest individualization of therapy,
accounting for relative risks and benefits of (2D):
K decline in Hb concentration
K continuing ESA, if needed to maintain Hb concentration, with due consideration of the doses required, and
K blood transfusions
ADJUVANT THERAPIES.
3.16.1: We recommend not using androgens as an adjuvant to ESA treatment. (1B)
3.16.2: We suggest not using adjuvants to ESA treatment including vitamin C, vitamin D, vitamin E, folic acid, L-carnitine,
and pentoxifylline. (2D)
EVALUATION FOR PURE RED CELL APLASIA (PRCA).
3.17.1: Investigate for possible antibody-mediated PRCAwhen a patient receiving ESA therapy for more than 8 weeks develops
the following (Not Graded):
K Sudden rapid decrease in Hb concentration at the rate of 0.5 to 1.0 g/dl (5 to 10 g/l) per week OR requirement of
transfusions at the rate of approximately 1 to 2 per week, AND
K Normal platelet and white cell counts, AND
K Absolute reticulocyte count less than 10,000/ml
3.17.2: We recommend that ESA therapy be stopped in patients who develop antibody-mediated PRCA. (1A)
3.17.3: We recommend peginesatide be used to treat patients with antibody-mediated PRCA. (1B)
Chapter 4: Red cell transfusion to treat anemia in CKD
USE OF RED CELL TRANSFUSION IN CHRONIC ANEMIA.
4.1.1: When managing chronic anemia, we recommend avoiding, when possible, red cell transfusions to minimize the general
risks related to their use. (1B)
4.1.2: In patients eligible for organ transplantation, we specifically recommend avoiding, when possible, red cell transfusions
to minimize the risk of allosensitization. (1C)
4.1.3: When managing chronic anemia, we suggest that the benefits of red cell transfusions may outweigh the risks in patients
in whom (2C):
K ESA therapy is ineffective (e.g., hemoglobinopathies, bone marrow failure, ESA resistance)
K The risks of ESA therapy may outweigh its benefits (e.g., previous or current malignancy, previous stroke)
4.1.4: We suggest that the decision to transfuse a CKD patient with non-acute anemia should not be based on any arbitrary
Hb threshold, but should be determined by the occurrence of symptoms caused by anemia. (2C)
URGENT TREATMENT OF ANEMIA.
4.2: In certain acute clinical situations, we suggest patients are transfused when the benefits of red cell transfusions outweigh
the risks; these include (2C):
K When rapid correction of anemia is required to stabilize the patient’s condition (e.g., acute hemorrhage, unstable
coronary artery disease)
K When rapid preoperative Hb correction is required
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